ARK Genomic Revolution ETF
ARKG
219 hedge funds and large institutions have $743M invested in ARK Genomic Revolution ETF in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 41 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 55
0.32% less ownership
Funds ownership: 72.38% → 72.06% (-0.32%)
8% less funds holding
Funds holding: 239 → 219 (-20)
13% less capital invested
Capital invested by funds: $854M → $743M (-$111M)
26% less call options, than puts
Call options by funds: $79.9M | Put options by funds: $108M
32% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$61M |
| 2 |
Goldman Sachs
New York
|
+$25M |
| 3 |
Morgan Stanley
New York
|
+$24.3M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$22M |
| 5 |
HI
Humankind Investments
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$59.2M |
| 2 |
Citigroup
New York
|
-$27.3M |
| 3 |
Jane Street
New York
|
-$14.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$14.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$11.8M |
ARKG Hedge Fund Activity: Q1 2026 in Review
219 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2026, worth a combined $743M — down 13% from $854M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of ARKG and 28 opened new positions — a net loss of 13 holders — while 55 trimmed existing stakes and 60 added.
The largest buyer was JP Morgan Chase, adding an estimated $61M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $59.2M.
- 219 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2026, down from 239 in Q4 2025.
- Funds reported $743M of ARK Genomic Revolution ETF stock for Q1 2026, down 13% quarter-over-quarter.
- 28 funds opened new ARK Genomic Revolution ETF positions in Q1 2026 and 41 closed out, a net change of -13 holders.
- The largest ARK Genomic Revolution ETF buyer in Q1 2026 was JP Morgan Chase, an estimated $61M added.
- The largest ARK Genomic Revolution ETF seller in Q1 2026 was BNP Paribas Financial Markets, an estimated $59.2M sold.
Based on aggregated 13F filings for Q1 2026.